An exciting project set to explore a newly discovered pathway that could lead to new treatments for metastatic prostate cancer is now underway at the Centre for Cancer Biology (CCB). Supported by Australian Prostate Cancer (APC), with partner The Hospital Research Foundation (THRF), this incredible, innovative research is set to save lives.
While advanced research has ensured that organ-confined prostate cancer is cured in about 70 per cent of cases, metastatic prostate cancer (where the cancer will or has spread around the body) is incurable.
These patients are treated with androgen deprivation therapy which is initially effective, but patients will eventually relapse and become resistant to their treatment. Therefore, there is a dire need to understand more about metastatic prostate cancer to identify novel therapeutic targets towards curing this disease.
Combining forces, Dr Philip Gregory, Professor Greg Goodall and Associate Professor Simon Conn from the CCB have identified a new molecular pathway that is likely to control whether a prostate cell remains benign or becomes more aggressive and metastasizes.
We are delighted to fund their pilot project, which will examine this pathway in metastatic prostate cancer samples from patients to assess its importance for patient outcomes to develop new treatments for advanced prostate cancer.
“We are thrilled to be supported by APC and THRF to get this project underway and contribute to a future free of prostate cancer. A pilot project is essential for us to get the initial data we need to take this research to the next phase,” said Dr Gregory.
We look forward to updating you on the outcomes of this exciting project in the near future.